Goldman Sachs Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $71

Benzinga Newsdesk www.benzinga.com Positive 58.3%

Neg 0% Neu 0% Pos 58.3%

Goldman Sachs analyst Scott Fidel initiates coverage on BrightSpring Health (NASDAQ:BTSG) with a Buy rating and announces Price Target of $71.